Abbott is preparing to train centers to treat severe tricuspid valve regurgitation with its TriClip G4 transcatheter edge-to-edge repair device now that US regulatory approval in 2024 is all but assured.
Wall Street analysts expect the US Food and Drug Administration to approve TriClip G4 in the next three to four...